Biomaterials Technology and Product Development
Our Biomaterials Technology and Product Development group is primarily involved with the translation of existing core technology platforms into medical devices to meet a variety of clinical needs. The current product focus is directed at the development of animal tissue derived devices employing adaptations of the company's decellularization technologies. The clinical areas targeted are:
Protein Hydrogel Technologies (PHT)
BioGlue® Surgical Adhesive and BioFoam® Surgical Matrix have been invented and/or developed by our PHT group. Six US Patents as well as a number of corresponding international patents support these technologies. The PHT group is charged with developing new products from CryoLife's Protein Hydrogel Technology platform, as well as investigating additional surgical adhesives and biomaterials based on other hydrogel technologies. The PHT group consists of chemists, biochemists, biologists, and engineers who are responsible for new formulations, manufacturing procedures, chemical, biochemical and mechanical test methods and delivery systems. Products in development are rigorously tested to establish specifications and validation parameters. Additional responsibilities of the PHT group include providing technical support for CryoLife's Regulatory Affairs, Clinical Research, Quality and Marketing.
The Tissue Technologies group investigates new technologies for the preparation of implantable cardiac and vascular tissues. These implants may come through novel methods of treating animal tissues to permit human transplantation without chemical fixation using decellularization technology or the masking of tissue antigens chemically preventing interaction with the human immune system. Presently, efforts include chemical treatments of animal tissues to improve their microbiological safety without compromising structural integrity of the tissue, as well as evaluating techniques to improve the patency of vascular allografts used for peripheral bypass and arteriovenous bypass grafting. With a general focus in tissue engineering and regenerative medicine, the group is investigating allograft tissue as a source of cells that could be used for diagnostic, quality, and therapeutic purposes.